Jain Global LLC Has $8.06 Million Stake in Insmed, Inc. $INSM

Jain Global LLC lowered its stake in Insmed, Inc. (NASDAQ:INSM) by 56.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 55,938 shares of the biopharmaceutical company’s stock after selling 71,223 shares during the period. Jain Global LLC’s holdings in Insmed were worth $8,056,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in INSM. Stone House Investment Management LLC acquired a new position in shares of Insmed during the 3rd quarter valued at about $29,000. SBI Securities Co. Ltd. lifted its holdings in Insmed by 404.9% in the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 166 shares during the last quarter. MassMutual Private Wealth & Trust FSB boosted its position in Insmed by 59.6% during the third quarter. MassMutual Private Wealth & Trust FSB now owns 217 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 81 shares during the period. Whittier Trust Co. of Nevada Inc. boosted its position in Insmed by 169.7% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 240 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 151 shares during the period. Finally, RiverPark Advisors LLC acquired a new position in Insmed during the third quarter valued at approximately $38,000.

Analysts Set New Price Targets

INSM has been the topic of a number of recent analyst reports. Bank of America set a $203.00 price target on shares of Insmed in a research report on Thursday, December 18th. Leerink Partners reiterated an “outperform” rating on shares of Insmed in a research note on Thursday, December 18th. UBS Group dropped their target price on shares of Insmed from $223.00 to $215.00 and set a “buy” rating on the stock in a report on Tuesday, January 6th. Citigroup reissued an “outperform” rating on shares of Insmed in a research report on Thursday, December 18th. Finally, Stifel Nicolaus set a $205.00 price target on shares of Insmed in a report on Thursday, February 19th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $205.57.

Insider Buying and Selling

In related news, CFO Sara Bonstein sold 748 shares of the firm’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $156.34, for a total transaction of $116,942.32. Following the completion of the transaction, the chief financial officer owned 79,758 shares in the company, valued at $12,469,365.72. This trade represents a 0.93% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Roger Adsett sold 791 shares of the business’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $156.17, for a total value of $123,530.47. Following the completion of the sale, the chief operating officer directly owned 106,810 shares in the company, valued at approximately $16,680,517.70. This represents a 0.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 189,651 shares of company stock valued at $31,784,545 over the last ninety days. Company insiders own 3.00% of the company’s stock.

Insmed Price Performance

NASDAQ:INSM opened at $144.60 on Tuesday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.54 and a current ratio of 3.83. The company has a 50-day moving average of $154.57 and a 200-day moving average of $166.22. Insmed, Inc. has a 52 week low of $60.40 and a 52 week high of $212.75. The company has a market capitalization of $31.17 billion, a price-to-earnings ratio of -22.56 and a beta of 1.13.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The business had revenue of $263.84 million during the quarter, compared to the consensus estimate of $263.97 million. During the same period in the previous year, the firm earned ($1.32) EPS. The business’s revenue was up 152.6% compared to the same quarter last year. As a group, equities research analysts anticipate that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.